IBI310

Phase 2Small molecule

Innovent Biologics (Suzhou) Co. Ltd.

IBI310 is one of 176 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Cervical CancerActive, not recruiting

Lung CancerPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Biliary Tract CancerPhase 1/Phase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2/Phase 3

Active, not recruiting

Gastric CancerPhase 1/Phase 2

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

IBI310

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Vermox

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Not yet recruiting

Hepatocellular Carcinoma

NCT07490262

Clinical

Trials by Indication[1]

Surufatinib1 trial

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Recruiting·PPeking University·Phase 2·NCT05165407·30 enrolled

Resistance1 trial

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04945421·30 enrolled

Lung Cancer1 trial

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05118334·30 enrolled

First-line Treatment1 trial

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04720716·344 enrolled

Cervical Cancer1 trial

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04590599·205 enrolled

6 more indications

Biliary Tract Cancer1 trial

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Unknown status· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT05653180·20 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT03545971·53 enrolled

Hepatocellular Carcinoma1 trial

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Not yet recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 2/3·NCT07490262·680 enrolled

Adult1 trial

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04868760·148 enrolled

Metastatic Colorectal Cancer1 trial

IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04258111·4 enrolled

Gastric Cancer1 trial

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Unknown status·PPeking University·Phase 1/2·NCT04202601·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for IBI310. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IBI310 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IBI310. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics (Suzhou) Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Innovent Biologics (Suzhou) Co. Ltd.

IBI310

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Surufatinib1 trial

Resistance1 trial

Lung Cancer1 trial

First-line Treatment1 trial

Cervical Cancer1 trial

Biliary Tract Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Hepatocellular Carcinoma1 trial

Adult1 trial

Metastatic Colorectal Cancer1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News